Tissue-type plasminogen activator: characteristics, applications and production technology.

Area of Science:

• Biotechnology
• Pharmacology
• Cardiovascular Medicine

Background:

• Plasminogen activators are crucial thrombolytic agents for treating stroke and myocardial infarction.
• Tissue-type plasminogen activator (tPA) is the preferred agent due to its efficacy and safety profile compared to urokinase or streptokinase.
• Advances in cell lines and bioprocess technology have enabled large-scale tPA production.

Purpose of the Study:

• To review current challenges and emerging trends in the production and application of plasminogen activators.
• To discuss strategies for enhancing cellular productivity and downstream product recovery of tPA.
• To explore the development of second-generation tPA molecules for improved fibrinolytic therapy.

Main Methods:

• Review of scientific literature on plasminogen activator production and clinical use.
• Analysis of advancements in bioprocess technology and cell line development.
• Examination of research efforts in modifying tPA for enhanced therapeutic properties.

Main Results:

• Large-scale tPA production is feasible due to technological advancements.
• High treatment cost remains a significant barrier to tPA accessibility.
• Ongoing research aims to improve tPA efficiency and develop superior fibrinolytic agents.

Conclusions:

• Despite its clinical importance, tPA's high cost necessitates further innovation in production and recovery.
• The development of next-generation plasminogen activators is crucial for advancing thrombolytic therapy.
• Future research should focus on cost-effective production and enhanced efficacy of fibrinolytic agents.